Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle comparator Clear all
Completed Phase 4 Interventional Results available

Wound Edge Changes Following Treatment With Santyl

NCT01197898
View directory record Official record
Conditions
Diabetic Foot Ulcers, Diabetic Foot Wounds
Interventions
Collagenase Santyl Ointment, Placebo Comparator
Biological · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

NCT02129660
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD, Dose 2 of glycopyrronium, 3.75% QD, Vehicle
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Encinitas, California • Fremont, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

NCT05238597
View directory record Official record
Conditions
Dry Eye Disease
Interventions
A197 Ophthalmic Solution, A197 Vehicle Control, Active Comparator
Drug
Lead sponsor
Aramis Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

NCT02930018
View directory record Official record
Conditions
Stroke, Acute
Interventions
Nerinetide (NA-1), 2.6 mg/kg, Placebo
Drug
Lead sponsor
NoNO Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 22, 2026, 4:13 AM EDT
Recruiting Phase 3 Interventional

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244
View directory record Official record
Conditions
Acute Ischemic Stroke, Cerebral Stroke
Interventions
Drug: Normal Saline, Sovateltide
Drug
Lead sponsor
Pharmazz, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

NCT03308799
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 cream, Cal/BDP combination, Cream vehicle
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Detroit, Michigan • Fridley, Minnesota • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Behavior Brain Responses

NCT03964350
View directory record Official record
Conditions
Alcohol Drinking, Drinking Behavior, Physiological Effects of Drugs, Central Nervous System Depression
Interventions
Ethanol, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

NCT01231373
View directory record Official record
Conditions
Varicose Veins
Interventions
polidocanol injectable foam, 0.125%, polidocanol injectable foam, 0.5%, polidocanol injectable foam, 1.0%, Vehicle
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
12
States / cities
Dothan, Alabama • San Diego, California • Lafayette, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Ketoconazole Cream 2%

NCT04203342
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Drug
Lead sponsor
Douglas Pharmaceuticals America Ltd
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Brandon, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

NCT04893486
View directory record Official record
Conditions
BCCs in Gorlin Syndrome Patients
Interventions
PTX-022, Vehicle comparator
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis

NCT02492321
View directory record Official record
Conditions
Allergic Conjunctivitis (AC)
Interventions
EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
11
States / cities
Morrow, Georgia • Louisville, Kentucky • Andover, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

NCT04753034
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TER-101, Vehicle
Drug
Lead sponsor
Teres Bio, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
12
States / cities
Scottsdale, Arizona • Encinitas, California • North Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 22, 2026, 4:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

NCT03954236
View directory record Official record
Conditions
Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
Interventions
topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2Phase 3 Interventional

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

NCT01670032
View directory record Official record
Conditions
Impetigo
Interventions
Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID, Placebo Comparator: CD07223 vehicle gel BID, Placebo Comparator: CD07223 vehicle gel TID
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

NCT05005845
View directory record Official record
Conditions
Cutaneous Neurofibroma, Neurofibromatosis 1
Interventions
NFX-179 gel, Vehicle gel
Drug
Lead sponsor
NFlection Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

NCT02672332
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
55
States / cities
Anaheim, California • Encinitas, California • Fresno, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 22, 2026, 4:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

NCT01235728
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

NCT03290027
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03, Placebo Comparator
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

NCT03064438
View directory record Official record
Conditions
Acne Rosacea
Interventions
ACCU-D1, Vehicle
Drug
Lead sponsor
Accuitis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Louisville, Kentucky • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

NCT02247804
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
56
States / cities
Phoenix, Arizona • Glendale, California • Irvine, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)

NCT00869336
View directory record Official record
Conditions
Tinea Pedis
Interventions
Luliconazole Cream 1% - 2 wks, Placebo Comparator -2 wks, Luliconazole Cream 1% - 4 wks, Placebo Comparator - 4 wks
Drug
Lead sponsor
Tinea Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Fridley, Minnesota • Portland, Oregon • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Results available

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

NCT03131167
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions
SHP639 (n=60), Placebo Comparator (n=24)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 22, 2026, 4:13 AM EDT